Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

NCT07653139 | Not Yet Recruiting

• 2 other identifiers: DAS-8858U1111-1336-6966
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.

Conditions

Haemophilia A

Outcome Measures

Primary Outcomes (1)

• Choice of treatment alternative in discrete choice tasks

  Categorical

  Day 1

Study Arms (1)

Cohort 1

Adults with haemophilia A with and without inhibitors

Other: No treatment given

Interventions

No treatment given OTHER

Web-based survey

Cohort 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with haemophilia A with and without inhibitors

You may qualify if:

• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
• Age above or equal to 18 years at the time of signing informed consent.
• Validated diagnose with haemophilia A, with and without inhibitors.
• Resident in Germany.

You may not qualify if:

• No provision of informed consent in this study.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
• Age below 18 years at the time of signing informed consent.
• Absence of a diagnosis of haemophilia A.
• No residence in Germany.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk Investigational Site

Mainz, Gonsenheim, 55124, Germany

Location

MeSH Terms

Conditions

Hemophilia A

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Central Study Contacts

Novo Nordisk

CONTACT

(+1) 866-867-7178; clinicaltrials@novonordisk.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2026
• First Posted: June 17, 2026
• Study Start (Estimated): July 10, 2026
• Primary Completion (Estimated): October 26, 2026
• Study Completion (Estimated): October 26, 2026
• Last Updated: June 17, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)